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Abstract
Background: Since 2003 Tanzania has upgraded its approximately 7000 drug stores to Accredited Drug Dispensing
Outlets (ADDOs), involving dispenser training, introduction of record keeping and enhanced regulation. Prior to
accreditation, drug stores could officially stock over-the-counter medicines only, though many stocked prescription-only
antimalarials. ADDOs are permitted to stock 49 prescription-only medicines, including artemisinin combination therapies
and one form of quinine injectable. Oral artemisinin monotherapies and other injectables were not permitted at any time.
By late 2011 conversion was complete in 14 of 21 regions. We explored variation in malaria-related knowledge and
practices of drug retailers in ADDO and non-ADDO regions.
Methods: Data were collected as part of the Independent Evaluation of the Affordable Medicines Facility - malaria
(AMFm), involving a nationally representative survey of antimalarial retailers in October-December 2011. We randomly
selected 49 wards and interviewed all drug stores stocking antimalarials. We compare ADDO and non-ADDO regions,
excluding the largest city, Dar es Salaam, due to the unique characteristics of its market.
Results: Interviews were conducted in 133 drug stores in ADDO regions and 119 in non-ADDO regions. Staff
qualifications were very similar in both areas. There was no significant difference in the availability of the first line
antimalarial (68.9% in ADDO regions and 65.2% in non-ADDO regions); both areas had over 98% availability of non-
artemisinin therapies and below 3.0% of artemisinin monotherapies. Staff in ADDO regions had better knowledge of
the first line antimalarial than non-ADDO regions (99.5% and 91.5%, p = 0.001). There was weak evidence of a lower
price and higher market share of the first line antimalarial in ADDO regions. Drug stores in ADDO regions were more
likely to stock ADDO-certified injectables than those in non-ADDO regions (23.0% and 3.9%, p = 0.005).
Conclusions: ADDO conversion is frequently cited as a model for improving retail sector drug provision. Drug stores
in ADDO regions performed better on some indicators, possibly indicating some small benefits from ADDO conversion,
but also weaknesses in ADDO regulation and high staff turnover. More evidence is needed on the value-added and
value for money of the ADDO roll out to inform retail policy in Tanzania and elsewhere.
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Background
In many developing countries the private sector has
played an increasingly important role in treatment seek-
ing in recent years, accounting for 40-60% of care-
seeking visits [1]. Treatment for common illnesses is
often obtained in drug shops, as there are frequent
stock-outs of essential drugs in the public sector, while
drug stores are often more geographically accessible
than public facilities, have longer opening hours, and
better stock availability [2]. However, there are concerns
that drug stores are poorly monitored and may be run
by under-qualified staff [3]. Working with such private
medicine sellers to improve their quality of care has
therefore been seen as a strategy to enhance overall
health service provision [4]. Strategies that have been
used include training of drug retailer staff, social market-
ing and social franchising [5–7].
In Tanzania the private drug retail sector has been
expanding rapidly. A study in three districts found that
the number of drug stores had doubled between 2004
and 2008 [2], while a study in three regions found that
54% of people with fever visited a drug store or phar-
macy for their first source of care in 2012, up from 41%
in 2010 [8]. Until 2003, the two types of retail outlets
permitted to sell drugs in Tanzania were pharmacies and
drug stores, the latter termed ‘duka la dawa baridi’
(DLDB) in Kiswahili. Tanzania has only around 700
pharmacies and they are mainly found in urban areas, so
the 7000-plus drug stores have been a crucial source of
care in rural and peri-urban areas [9, 10]. Drug store
staff were required to have at least 4 years of health-
related training, and were officially allowed to stock
over-the-counter medication (OTC) only, but often also
sold prescription only medicines (POMs) [11]. Further
concerns about their operations related to evidence of
inadequate facilities for storing medications, under-
qualified staff, and the limited supervision received from
inspectors [9, 11]. A small proportion of general retailers
also stocked OTCs, although they were not permitted to
do so [12].
Since 2003 the Tanzanian Government, with support
from Management Sciences for Health, has aimed to
improve healthcare provision in the retail sector by up-
grading drug stores to Accredited Drug Dispensing Out-
lets (ADDOs), with the aim of increasing access to certain
POMs and to good quality pharmaceutical services,
especially in rural areas where there are few registered
pharmacies [9]. Upgrading involves a 35-day dispenser
training for outlet staff, covering a number of medical
issues such as dispensing antimalarials, Integrated
Management of Childhood Illnesses (IMCI), family plan-
ning and HIV/AIDS care, as well as introduction of record
keeping [13]. Regulation is also supposed to be enhanced
through monitoring and evaluation by ward and district
officials to strengthen local regulatory capacity [14].
ADDOs are permitted to stock a specified list of 49 POMs.
Non-ADDO drug stores are officially not permitted to exist
in ADDO regions.
The Ministry of Health and Social Welfare decided to
roll out the ADDO programme nationwide starting in
2006. Roll out occurred by region, with the intention of
covering the more rural areas first [9]. By the end of
2010, eight of Tanzania’s then 21 regions had been
upgraded, with a further six completed in early 2011,
and all remaining regions covered by 2013 [15]. In
addition, a one-day retraining programme covering
malaria, including how to dispense ACTs, IMCI and
family planning was conducted in two regions in August
and September 2011.
While there is a substantial literature on the ADDO
programme [2, 3, 9, 10, 16–19], few studies have aimed
to evaluate drug store accreditation by presenting com-
parable data on ADDO and non-ADDO drug stores. A
few studies have compared ADDOs with other types of
provider such as public health facilities [20, 21] or
pharmacies [22], but only two studies compared ADDOs
with non-ADDOs, only one of which focused on malaria
treatment [23, 24]. A pilot of the ADDO programme
was evaluated by the ADDO implementing team in
2003-2004 by comparing ADDOs in four districts of
Ruvuma region in southern Tanzania with DLDB in four
comparison districts in Singida region in central Tanzania,
documenting mixed effects on malaria treatment quality
[23]. In ADDO districts, the percentage of stores stocking
the first line antimalarial (then sulfadoxine-pyrimethamine
(SP)) increased by 15 percentage points, and the percentage
of antimalarial medicines dispensed according to national
treatment guidelines by 26 percentage points, while both
indicators changed little in non-ADDO districts. However,
the percentage of simulated malaria clients advised how to
take medications fell in ADDO districts while remaining
constant in non-ADDO districts. At endline there was no
difference in the price of the first line antimalarial between
ADDO and non-ADDO districts [23]. An independent
study in 2011 compared three ADDO districts in Morogoro
region with one non-ADDO district in neighbouring Pwani
region, using simulated clients. They found no difference
between ADDO and non-ADDO districts in a wide variety
of inappropriate behaviours around antibiotic provision,
including readiness to administer injections and dispense
under-doses, with ADDOs actually more likely to dispense
antibiotics without a prescription than non-accredited
shops [10, 24]. Notably the authors found that 40% of
dispensers trained under the ADDO programme no longer
worked at the ADDO, with indications that they had
frequently been replaced with untrained staff.
In 2011 a nationally representative survey of antimalarial
providers was conducted throughout mainland Tanzania,
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to provide endline data for the Independent Evaluation of
the Affordable Medicines Facility - malaria (AMFm), a
multi-national antimalarial subsidy programme [15]. As at
this time the ADDO roll out was partially complete,
covering 14 out of the 21 regions, the survey provides the
opportunity to compare performance of drug retailers in
many regions with and without the accreditation
programme in terms of their malaria-related practices.
The survey provides data on a range of malaria-related in-
dicators, including antimalarial availability, price and sales
volumes, and malaria-related knowledge of outlet staff.
Results from this survey indicated drug stores, including
DLDB and ADDOs, accounted for 90% of all outlets
stocking an antimalarial in 2011, while 3% were pharma-
cies and 7% general retailers.
In mainland Tanzania the artemisinin based combin-
ation therapy (ACT) artemether lumefantrine (Alu) has
been the first line treatment for uncomplicated malaria
since 2006, with quinine as second line. In 2011 ACT
use was still quite low, with only 33% of children under
five with a febrile illness obtaining an ACT [25]. Many
people still took non-artemisinin therapies such as SP,
especially in the private sector where they were a much
cheaper alternative to ACTs. Officially Alu and quinine
were POM and could be sold in pharmacies and
ADDOs, but not DLDB. SP and amodiaquine could be
bought OTC in any drug retailer, while all other antima-
larials were POM and officially restricted to pharmacies
[13]. Quinine dihydrochloride injectables were allowed
in ADDOs but not DLDB, while all other injectables
were prohibited in both. Oral artemisinin monotherapies
were banned in Tanzania in 2008, reflecting concern that
their use may contribute to artemisinin resistance (non-
oral artemisinin monotherapies were still permitted for
treatment of severe malaria) [26]. Malaria diagnostic
tests (microscopy and rapid diagnostic tests (RDTs))
were not permitted in any drug stores.
The AMFm was implemented at national scale in
Tanzania and six other countries from 2010 onwards.
Hosted by the Global Fund to Fight AIDS, Tuberculosis
and Malaria, AMFm aimed to increase availability, af-
fordability and use of quality-assured ACTs, and crowd
out oral artemisinin monotherapies from the market
[27]. Quality-assured ACTs are ACTs that comply with
the Global Fund’s quality assurance policy [28]. Subsi-
dised ACTs were distributed through the public and
private sector, including through ADDOs and DLDB, with
supporting training and communications interventions. All
subsidised ACTs had a green leaf logo on the packet and
had a recommended retail price (RRP) of 1,000TSh ($0.64)
for an adult dose in mainland Tanzania. Supporting inter-
ventions such as national level communication campaigns
and local level community training were implemented
alongside the main intervention. Television, newspaper and
radio campaigns were conducted throughout the country,
while community level dissemination was limited to two
districts in each of 12 selected regions. The Independent
Evaluation showed that AMFm increased access to ACTs
in the private drug retail sector, with the availability of
quality-assured ACTs increasing from 10% to 66% in this
sector between 2010 and 2011 [8].
In this paper we explore variation in drug retailer
performance across ADDO and non-ADDO regions
following AMFm implementation, comparing staff know-
ledge of the first line drug and ACT dosing; whether
outlets stocked recommended and non-recommended
malaria-related products; antimalarial retail prices and
mark-ups; and the market share of recommended antima-
larials. The data collected provide a unique opportunity to
add to the limited evidence on the effects of drug
store accreditation, and represent the first study on a
national scale.
Methods
A nationally representative outlet survey was conducted
between October 2011 and January 2012 [15]. Data were
collected as part of the AMFm Independent Evaluation,
with the sample size determined by the needs of the
Independent Evaluation (full details available in Tougher
et al.) [12]. Forty-nine wards were randomly selected
using probability proportional to population size, strati-
fied by urban/rural location. Wards were designated as
urban or rural using National Bureau of Statistics
Census classifications, with mixed wards classified as
urban if more than 70% of the ward was classified as
urban. We selected 20 urban and 29 rural wards, and in
each selected ward all public and private outlets with the
potential to stock antimalarials were visited, though only
data on ADDOs and DLDB are presented in this paper.
In large wards with a population over 30,000 people,
wards were segmented, and one or more segments of
the ward were randomly selected for the survey.
Screening criteria were used to identify outlets with an
antimalarial in stock at the time of visit or within the
previous 3 months. Following verbal consent, a ques-
tionnaire was conducted with the most senior staff
member present, in Kiswahili, with data collected using
Personal Digital Assistants (PDAs). Questions about out-
let characteristics were asked, and details about every
antimalarial in stock at the time of visit were recorded,
as well as the volumes of each product sold in the past 7
days. Data collectors were grouped into teams of a
supervisor, quality control officer and four interviewers,
who all underwent two-weeks training. The quality con-
trol officer was responsible for ensuring that all eligible
outlets had been visited, and revisiting a random sample
of outlets to conduct spot-checks and ensure that all an-
timalarials had been recorded correctly.
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For the purposes of this paper antimalarials were clas-
sified into four categories: (i) Alu, the first line drug in
mainland Tanzania; (ii) other ACTs; (iii) artemisinin
monotherapies, including oral and non-oral forms; and
(iv) non-artemisinin therapies such as SP, quinine,
chloroquine, mefloquine and amodiaquine. For some
analysis Alu was further divided into those with the
green leaf logo (i.e. AMFm subsidised drugs) and those
without, and injectables were divided into ADDO-
certified injectables, i.e. those permitted to be sold in
ADDOs but not non-accredited drug stores, and non
ADDO-certified injectables, i.e. those forbidden to be
sold in all drug stores. Price data are presented separ-
ately for antimalarials in tablet and non-tablet form
(including syrups, suspensions, granules and injectables),
as non-tablet antimalarials have a different price distri-
bution and tend to be more expensive than tablets, so
stratifying by dosage type ensures prices and mark-ups
are comparable across antimalarial categories. Price and
market share data were calculated using Adult Equiva-
lent Treatment Doses (AETDs), the amount of a drug
needed to treat a 60 kg adult [29]. For example, to calcu-
late the price per AETD of a paediatric package of Alu
with 6 standard tablets (20 mg artemether and 120 mg
lumefantrine), the price would be multiplied by 4 to cal-
culate the cost of an adult equivalent dose of 24 tablets.
Market share was calculated separately for ADDO and
non-ADDO regions by dividing the number of AETDs
of a particular antimalarial category sold by the total
number of AETDs of all antimalarials sold.
Drug stores were categorised into two groups depend-
ing on their location: ADDO regions and non-ADDO
regions. Drug store classification was based on region,
rather than the official status of individual drug stores,
as the ADDO intervention was implemented at a re-
gional scale, and DLDB were officially not permitted in
ADDO regions. In practice some drug stores operating
in ADDO regions have not undergone the official
ADDO upgrading or the staff who participated in this
have moved on, but it is not always possible to identify
these stores. Therefore we use the term “drug stores” to
refer to both ADDOs and DLDBs, which are then classi-
fied by their location.
Dar es Salaam, Tanzania’s largest city and commercial
centre, was a non-ADDO region at the time of data col-
lection, but we excluded this region from the analysis as
the nature of its retail drug market is very different from
the rest of the country, as illustrated in the comparison
of the characteristics of ADDO regions, non-ADDO re-
gions and Dar es Salaam in Table 1. ADDO and non-
ADDO regions were similar in terms of the percentage
of households surveyed in in urban areas, the percentage
of households classified in the poorest two socio-
economic quintiles, and the percentage living within 10
min of a water source, though people in ADDO regions
were significantly more likely to live within 2 km of a
health facility [25]. Dar es Salaam’s characteristics were
very different, with the vast majority of the population
being urban and 0% of households surveyed classified in
the bottom two socio-economic quintiles. Including Dar
es Salaam in the analysis would therefore have compro-
mised the comparability of the two groups.
Data analysis was performed using Stata v11, and Stata
survey procedures were used to account for the survey
design and stratification. Differences in availability and
knowledge were assessed using the F-based design test,
and differences in price by the Wilcoxon rank sum test.
2011 prices were converted to 2010 prices using the
Tanzania consumer price index, and were converted to
US$ using the average interbank rate for 2010
(www.oanda.com) as is standard practice for the AMFm
Independent Evaluation [12].
Key informant interviews were conducted in December
2011 at national, regional and district level to gather infor-
mation about AMFm implementation, other malaria-
related interventions, and any other relevant contextual
factors that could have impacted on malaria treatment
outcomes during the study period. A total of 26 interviews
were conducted with 37 people from government bodies
(e.g. National Malaria Control Programme, Tanzania Food
and Drug Authority, regional and district health author-
ities) and non-governmental organization (e.g. Clinton
Table 1 Comparison of the characteristics of the total population by areaa
ADDO regions Non-ADDO regions
(excluding Dar es Salaam)
Dar es Salaam
Percentage of households surveyed who:
Live in urban areasb 18.8 16.5 95.8
Are in the lowest 2 socio-economic quintilesc 45.1 (40.9–49.3) 43.5 (38.4–48.7) 0.0
Live within 2 km of a health facilityc 37.5 (32.7–42.5) 22.3 (17.7–27.7) 42.1 (24.3–62.3)
Live within 10 min of a water sourcec 34.6 (30.9–38.6) 33.5 (28.6–38.7) 77.4 (69.1–83.9)
aIncludes entire population of these regions (not restricted to sampled wards)
bNational Bureau of Statistics Census classifications, 2012
cTanzania HIV/AIDS and Malaria Indicator Survey, 2011 [25]
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Health Access Initiative) [30]. Interviews followed a
semi-structured interview guide, and were recorded when
permission was granted, with notes also taken during the
interview. The information gathered was organized by
thematic codes, and the findings across interviews synthe-
sized in a report [15]. We draw on information from these
interviews in the discussion section of the paper.
Ethical approval was obtained from the Tanzanian
National Institute for Medical Research, the Institutional
Review Board of the Ifakara Health Institute, the London
School of Hygiene and Tropical Medicine Research
Ethics Committee, and the Institutional Review Board of
ICF International.
Results
We visited 148 drug stores in ADDO regions and 127 in
non-ADDO regions (Table 2), of which 133 and 119
respectively were interviewed. 1833 antimalarials were
recorded in these outlets.
Table 3 shows the characteristics of staff employed by
the drug stores at the time of the survey (including all
staff, not only those working at the time of data collec-
tion). The percentage of drug stores with at least one
member of staff who had completed secondary school
was 87.8% in ADDO regions and 89.3% in non-ADDO
regions (p = 0.75). Over 96% of drug stores in both areas
had a staff member with a health-related qualification.
Nurse assistants, who generally have just 1 year of train-
ing, were the most common cadre of health workers in
both areas, present at 64.2% of drug stores in ADDO
regions and 59.1% in non-ADDO regions. There were
no substantial differences in staffing between regions for
any health-related cadres.
Knowledge of the first line antimalarial was higher
among staff in ADDO regions than in non-ADDO
regions (99.5% and 91.4% respectively, p = 0.001)
(Table 4). Over 96% of staff in drug stores stocking
quality-assured ACTs could state the correct dose of an
ACT in adults,1 and over 90% in children, with no differ-
ence between areas in knowledge.
AMFm subsidised Alu was stocked by 67.0% of drug
stores in ADDO regions and 65.2% in non-ADDO re-
gions (Fig. 1). There was no difference between the two
areas in the availability of any type of Alu (68.2% in
ADDO regions and 65.2% in non-ADDO regions, p =
0.74), or of other ACTs (11.9% and 20.7%, p = 0.32). In
both areas artemisinin monotherapy was available at less
than 3% of drug stores, while by contrast nearly 100%
had a non-artemisinin therapy.
There was a substantial difference in the proportion of
drug stores that stocked an injectable antimalarial be-
tween ADDO and non-ADDO regions (25.0% and 3.9%
respectively, p = 0.003). The majority of these were the
quinine injectable that ADDOs are permitted to stock,
with 23.0% and 3.9% of drug stores in ADDO and non-
ADDO regions stocking ADDO-certified injectables
Table 2 Description of drug stores visited by area
ADDO regions Non-ADDO
regions
Total
Number of drug stores:
Enumerateda 148 127 275
Screened 134 119 253
Which met the screening
criteriab
133 119 252
With an antimalarial in
stock on the day of visit
133 118 251
Number interviewed 133 119 252
Number of antimalarials
recorded in drug stores
906 927 1833
aOutlets where at a minimum basic descriptive information was collected
bOutlets that had antimalarials in stock on the day of the survey or had
stocked antimalarials in the past 3 months
Table 3 Characteristics of staff employed at the time of the survey of drug stores interviewed
ADDO regions (N = 133) Non-ADDO regions (N = 119)
Number of staff who usually dispense drugs (median and interquartile range) 1 [1, 2] 1 [1, 2]
Percentage (95% CI) of outlets with at least onea:
Person with a health-related qualification 96.1 (89.1–98.7) 96.2 (86.6–99.0)
Pharmacist 5.6 (2.2–13.6) 4.7 (1.8–11.6)
Pharmacy technician 6.1 (3.2–11.2) 5.9 (2.5–13.2)
Medical doctor 13.0 (8.3–19.9) 7.8 (3.8–15.4)
Assistant medical officer/Clinical officer/Assistant clinical officer 17.7 (12.0–25.4) 11.2 (7.1–17.2)
Nurse/midwife 7.2 (3.2–15.3) 13.3 (7.2–23.3)
Nurse assistant 64.2 (54.6–72.9) 59.1 (49.7–67.8)
Person who finished secondary school 87.8 (77.7–93.7) 89.3 (82.4–93.7)
*Denotes p-value < 0.05
aIncluding the owner
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(p = 0.005) (Fig. 1). Non ADDO-certified injectables
were available in under 5% of drug stores in both
areas. Availability of malaria diagnostics was lower in
ADDO regions (0.3%) than in non-ADDO regions
(4.5%) (p = 0.003).
In outlets which did not stock a quality-assured ACT,
staff were asked why they did not provide these prod-
ucts. 26.1% in ADDO regions and 24.0% in non-ADDO
regions said they were “temporarily out of stock”. The
next two most common responses in both areas were
that “customers don’t ask for them” (20.6% in ADDO
regions, 25.3% in non-ADDO regions), and that they
were “too expensive” (25.4% in ADDO regions, 17.3% in
non-ADDO regions). There was no difference in the
proportion of people who stated regulatory reasons for
not stocking between ADDO and non-ADDO regions,
with 16.4% of staff in ADDO regions and 17.2% non-
ADDO regions saying that the outlet was not allowed to
sell them.
The median cost of subsidised Alu was slightly cheaper
in ADDO regions, at $0.83 per AETD in drug stores in
ADDO regions compared with $0.94 in non-ADDO re-
gions (p = 0.005) (Table 5). The same pattern was seen
with unsubsidised Alu tablets, which had a median price
of $1.00 per AETD in ADDO regions and $1.25 in non-
ADDO regions (p = 0.04). By contrast, the median price of
non-artemisinin therapy tablets per AETD was higher in
ADDO regions ($0.94 compared with $0.75 in non-
ADDO regions). There was no significant difference in the
percentage mark-up for any drug category between
ADDO and non-ADDO regions, except for unsubsidized
Alu tablets, for which the mark-up in ADDO regions was
nearly double that in non-ADDO regions (100.0% and
53.1% respectively, p < 0.05) (Table 6).
The market share of subsidised Alu was 38.0% in ADDO
regions and 24.7% in non-ADDO regions (p = 0.10)
(Fig. 2), with the market share of all types of Alu com-
bined only slightly higher at 41.6% and 25.1% (p = 0.07) re-
spectively. The market share of non-artemisinin therapies
was higher in non-ADDO regions (73.3%) than ADDO re-
gions (57.3%) (p = 0.08). For artemisinin monotherapies
the market share was below 0.1% in both areas.
Discussion
Since these data were collected the ADDO programme
has been rolled out nationwide in Tanzania, and the
model has been adopted or adapted in several other
countries, including Ghana, Uganda and Liberia [16]. It
is often cited as an important model for improving retail
sector drug provision, with frequent suggestions that it
can be used as a platform for expanding access to other
public health commodities and services, such as family
Table 4 Knowledge of drug store staff on the first line antimalarial and ACT dosing recommendations
ADDO regions Non-ADDO regions
N % (95% CI) N % (95% CI)
Could correctly state the first line antimalarial 133 99.5 (96.3–99.9) 119 91.5 (77.3–97.1)*
Could correctly state the dosing of a quality-assured ACT in adultsa 87 98.2 (92.1–99.6) 75 96.3 (89.6–98.7)
Could correctly state the dosing of a quality-assured ACT in childrena 78 90.5 (75.4–96.7) 69 95.0 (87.3–98.1)
*Denotes p-value < 0.05
aOutlet staff were asked about the correct dosing of a quality-assured ACT if they had at least one quality-assured ACT in stock on the day of visit
Fig. 1 Availability of antimalarials and blood tests in drug stores by area. *: p < 0.05. Whiskers denote 95% confidence intervals. Blood test
includes microscopy or rapid diagnostic test
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planning and integrated fever management [31].
However, the model is also acknowledged to face a
number of challenges, including difficulties in providing
consistent supervision and oversight for a large and
growing number of ADDOs, and in maintaining a
trained cadre of staff given the high turnover among dis-
pensers [13, 24]. Evaluation of the programme’s perform-
ance is therefore very important. This paper compares
practices in drug stores in regions that had undergone
drug store accreditation with those that had yet to be
accredited to assess how the ADDO programme affected
antimalarial dispensing practices in drug stores.
In common with the two previous studies comparing
ADDO and non-ADDO areas [23, 24], we find a mixed
picture with ADDOs performing better on some dimen-
sions though not on others. Before discussing these
findings we note a number of study limitations. Firstly,
classification of drug stores was based on region, not
individual outlet. The ADDO roll out was implemented
by region, so all drug stores in ADDO regions should
have been ADDOs and vice versa, but sometimes this
was not the case in practice. ADDOs could have moved
to non-ADDO regions after being accredited, and some
drug stores in ADDO regions were not accredited, for
Table 5 Retail price of antimalarials per adult equivalent treatment dose in drug stores by areaa
ADDO regions Non-ADDO regions
N Median Price [IQR] N Median Price [IQR]
Artemether lumefantrine
Subsidisedb tablets 180 0.83 [0.62–1.25] 150 0.94 [0.83-1.25]*
Unsubsidised tablets 15 1.00 [0.62-1.25] 7 1.25 [1.00-6.25]*
Unsubsidised non-tablets 5 16.66 [15.00-16.66] 14 16.66 [15.00 – 16.66]
Other ACTs
Tablets 48 6.25 [3.12-12.50] 87 6.25 [3.12-11.52]
Non-tablets 0 – 2 28.75 [20.00-37.50]
Artemisinin monotherapies
Non-tabletsc 1 22.50 0 –
Non-artemisinin therapies
Tablets 387 0.94 [0.62-1.31] 376 0.75 [0.56-0.94]
Non-tablets 268 3.57 [2.81-21.97] 289 2.81 [1.87-16.48]*
*denotes p < 0.05
aPrices given in 2010 USD equivalent
bArtemeter lumefantrine was identified as subsidised if it bore the AMFm green leaf logo on its packaging
cNo oral artemisinin monotherapies were recorded in drug stores
Table 6 Percentage retail mark-up on antimalarials in drug stores by area
ADDO regions Non-ADDO regions
N Median Mark-up [IQR] N Median Mark-up [IQR]
Artemether lumefantrine
Subsidiseda tablets 75 60.0 [33.3–78.6] 90 66.7 [42.9–87.5]
Unsubsidised tablets 6 100.0 [66.7–102.5] 5 53.1 [50.0–66.7]*
Unsubsidised non-tablets 3 28.20 [20.0–47.1] 6 47.06 [33.3–50.0]
Other ACTs
Tablets 22 42.9 [32.2–53.8] 45 33.3 [− 61.1–66.7]
Non-tablets 0 – 1 11.1
Artemisinin monotherapies
Non-tabletsb 1 50.0 0 –
Non-artemisinin therapies
Tablets 141 81.8 [28.6–100.0] 167 87.5 [33.3–110.5]
Non-tablets 112 66.7 [42.9–87.5] 136 50.0 [33.3–81.8]
*denotes p < 0.05
aArtemether lumefantrine was identified as subsidised if it bore the AMFm green leaf logo on its packaging
bNo oral artemisinin monotherapies were recorded in drug stores
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example if the drug store opened after upgrading had
taken place in that region, or the outlet staff had been
unable to attend ADDO training. However, as the
ADDO roll out was considered to be implemented on a
region by region (rather than outlet by outlet) basis, we
felt that this approach to drug store classification was
appropriate.
Secondly, the selection of regions that had received
ADDO roll out at the time of the study was not random,
but rather depended on the choices of Tanzanian
Government and their partners. This raises the concern
that there could have been other differences between
ADDO and non-ADDO regions apart from ADDO roll
out. It is reassuring to note the similarity of the two
areas on key demographic indicators (Table 1), but
differences could also have arisen due to variation in im-
plementation of AMFm or other malaria-related interven-
tions, or due to other contextual factors. To assess this we
drew on key informant interviews at national, regional
and district level to identify other possible factors that
could have affected our results [30]. The interviews indi-
cated that implementation of AMFm supporting interven-
tions was relatively uniform across the country, as it relied
primarily on mass media. Local level communications ac-
tivities were held in selected districts only, but these were
very small scale, and held in half of the ADDO regions
and half the non-ADDO regions, so are unlikely to have
affected the relative performance of these areas in our
findings. A separate USAID-funded malaria communica-
tions and training campaign was conducted at the time,
but again the target districts were evenly spread between
ADDO and non-ADDO regions. The key informant
interviews did not identify any other interventions or
contextual factors likely to have affected our indicators.
A third limitation is that results were based on
reported data from outlet staff, and may have been sub-
ject to recall bias, or staff may have biased their answers
if they were worried about acting outside the regulations.
For example, staff may not have declared POMs they
were not allowed to sell, which could particularly have
led to under-reporting of ACT availability in non-ADDO
regions where drug stores were not allowed to stock
these POMs. Staff may also have understated their retail
price for subsidised ACTs if they were charging more
than the RRP. Finally, this study is based on the range of
performance measures available in the outlet survey
related to antimarial provision and malaria-related
knowledge. Other indicators such as antimalarial
dispensing practices and appropriate referrals have not
been captured, and non-malarial products such as anti-
biotics have not been included.
Dimensions of performance which were similar in ADDO
and non-ADDO regions
Drug stores in ADDO regions and non-ADDO regions
performed similarly on a number of indicators. For
example, the percentage of drug stores with a staff member
with a health-related qualification was very high in both
areas, although by far the most common cadre of staff in
both areas was nurse assistant, which requires just 1 year of
training. Knowledge of dosing recommendations was
similar in both areas, with over 90% of staff stocking
quality-assured ACTs able to state their dosing recommen-
dations correctly in all areas.
There was also no difference in availability of any anti-
malarial drug categories between drug stores in ADDO
regions and non-ADDO regions, apart from ADDO-
certified injectables which were more common in ADDO
Fig. 2 Antimalarial market share - percentage breakdown of antimalarials sold/distributed in drug stores by area1.*: p < 0.05. 1Antimalarials sold/
distributed in the week preceding the survey visit were included in this analysis
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regions (discussed below). Drug stores in non-ADDO re-
gions were not permitted to stock Alu or other ACTs, so
their high availability could indicate a lack of supervision
of drug shops in these regions. However, the regulatory
authorities in Tanzania have reported that they chose not
to enforce the regulation restricting Alu sales strongly in
rural areas, due to lack of alternative legitimate private
providers and frequent public sector stock outs [3, 15]. In-
deed there was no difference in the proportion of drug
store interviewees who stated regulatory reasons for not
stocking quality-assured ACTs between ADDO and non-
ADDO regions.
Availability of non-artemisinin therapies was very high
in ADDO and non-ADDO regions, with the most com-
monly sold antimalarial in this category being SP, an
OTC medication. Given SP’s previous status as first line
drug, its relatively low price, and the fact that both
ADDOs and non-ADDOs are permitted to sell such
OTCs, it was not surprising to see high availability and
market share of non-artemisinin therapies in both areas.
In contrast, artemisinin monotherapies were banned in
both drug store types, and availability and market share
was minimal in both areas.
Dimensions of performance which were better in ADDO
regions
Despite these similarities, drug stores in ADDO regions
performed better than those in non-ADDO regions in
some respects. Although there was no difference in Alu
availability between the two areas, there was weak evi-
dence to show that drug stores in ADDO regions had a
higher Alu market share than those in non-ADDO re-
gions, while the reverse was true for non-artemisinin
therapies. This might be explained by several factors.
First, it could have reflected lower Alu prices; while the
median Alu price exceeded the RRP in both ADDO and
non-ADDO regions, it was closer to the RRP in ADDO
regions, with a median $0.11 less per AETD than in
non-ADDO regions. Higher Alu market share could also
partly reflect the better knowledge of the first line
antimalarial in ADDO regions, though knowledge was
above 90% in all areas. Staff in ADDOs may have felt a
greater sense of responsibility and confidence to provide
advice about the recommended antimalarial to their
customers due to the training they received as part of
the ADDO upgrading programme. It could also have
reflected the greater proximity of the population in
ADDO regions to health facilities (Table 1) which may
have facilitated communication on the first line antimal-
arial to community members.
The availability of non ADDO-certified injectables was
low in all areas, while the availability of ADDO-certified
injectable antimalarials was very low in non-ADDO re-
gions and significantly higher in ADDO regions. This
was mainly due to the presence of quinine dihydrochlor-
ide injectables, which are permitted in ADDOs but not
in unaccredited drug stores. In contrast, a higher
proportion of outlets had blood testing available in non-
ADDO regions; as blood tests were not permitted in
either drug store type, this could suggest the need for
stricter regulations and supervision in this area. How-
ever, in response to data that show that the majority of
people purchasing ACTs in drug stores are not infected
with malaria [32], the Tanzanian government and
partners have piloted the promotion of rapid diagnostic
tests for malaria in drug stores, so the regulatory status
of blood testing may be reviewed [33].
Conclusion
The ADDO model has now been rolled out nationwide in
Tanzania and emulated in a number of other countries.
This study showed that performance on some malaria-
related indicators was better in ADDO regions than in
other areas. However, these differences were relatively
small, and there was no difference on several other mea-
sures of performance. Even where ADDO regions did
perform somewhat better than non-ADDO regions, there
was still considerable room for improvement, with 31% of
drug stores in ADDO regions not stocking the first line
antimalarial, and non-artemisinin therapies continuing to
account for nearly 60% of the antimalarial market, despite
ACT subsidies implemented under AMFm.
On the basis of these results alone one would be cau-
tious about promoting the ADDO model, although we
recognize that this paper’s results cover a limited range of
malaria-related indicators, accounting for only one area of
ADDO performance. Unfortunately other literature
comparing ADDOs with non-ADDO drug stores is lim-
ited and inconsistent, comprising one positive internal
evaluation of the pilot programme [23], and one more
negative independent evaluation [24]. Thus, while these
results contribute to the literature in this area, to make
evidence-based decisions on drug shop policy, it will be
essential that robust evaluations of any future ADDO-
style programmes are conducted, to assess their perform-
ance across a wide range of indicators, and to explore
their cost-effectiveness compared to alternative ap-
proaches to improve case management in the community.
Endnotes
1Dosing knowledge was only tested in outlets stocking
quality-assured ACTs. Dosing was categorized as correct
if the interviewee could correctly state the state the num-
ber of tablets to be taken, the number of times per day
and over how many days the tablets should be taken.
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